Phase 3Not yet recruiting
Impact of Semaglutide in Liver Transplant Candidates with Obesity (SOMAL Study): A Prospective Randomized Study. (IMIB-SML-2026-03)
- Sponsor
- Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia (Industry)
- Enrolment
- 50 planned
- Conditions
- Arterial hypertension; Type 2 diabetes mellitus; Obesity; Dyslipidaemia; Liver transplant
- Interventions
- Wegovy 1 mg FlexTouch solution for injection in pre-filled pen; Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen; Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen; Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen; Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen
- Ages
- adults, older adults
- Registry
- CTIS2026-526953-32-00
Full record on the EU Clinical Trials Information System
From the registry
Main objective: To assess the efficacy and safety of semaglutide in liver transplant candidates in terms of weight loss and metabolic control.
Primary outcomes
- Percentage change in body weight from the start of treatment to the time of liver transplant, comparing semaglutide with standard treatment.
History
Registered